During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.
But how do killer T cells “learn” to leave their home base and amass within specific tissues like the skin, gut, and lung, or solid tumors? Finding the factors that cause T cells to function beyond the lymphoid system and in sites of infection or cancer has proven a tough challenge, but it’s essential for developing cancer-fighting immunotherapy strategies.
Writing in the journal Nature, researchers from The Scripps Research Institute and the University of California, San Diego report the discovery that a protein called “Runx3” programs killer T cells to establish residence in tumors and infection sites.
“Runx3 works on chromosomes inside killer T cells to program genes in way that enables the T cells to accumulate in a solid tumor,” said Matthew Pipkin, Ph.D., associate professor in the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute.
The paper, “Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumors,” appears in Nature’s Dec. 14 issue.
There are two main strategies in cancer immunotherapy that employ killer T cells, Pipkin said. Checkpoint inhibitor blockade unleashes killer T cells, prompting them to accumulate in tumors more aggressively. Adoptive cell transfer, meanwhile, involves re-infusing a patient’s own immune cells after they have been engineered in the lab to recognize and destroy the patient’s specific cancer.
The adoptive cell transfer strategy has worked stunningly well in some blood cancers associated with the lymphoid system, so far. But there appears to be less efficient activity of T cells in solid tumors, Pipkin said.
“The gene programs and signals for how the T cells take up residence in tissues outside of the general circulation was not really well understood,” Pipkin said.
To discover factors that control T cell residency beyond the lymphoid system, Pipkin’s team worked collaboratively with the laboratory of UC San Diego’s Ananda Goldrath, who compared the gene expression of CD8+ T cells found in non-lymphoid tissue to those found in the general circulation. From a list of potential factors, they employed an RNA interference screening strategy which can test the actual function of thousands of factors simultaneously. Pipkin’s lab had developed the screening strategy in collaboration with Shane Crotty at the La Jolla Institute for Allergy and Immunology.
“We found a distinct pattern,” Pipkin said. “The screens showed that Runx3 is one at the top of a list of regulators essential for T cells to reside in nonlymphoid tissues.” Moreover, Runx3 was able to engage a specific gene program that is found in natural tissue-resident and tumor infiltrating CD8+ T cells, he said.
The group further assessed whether Runx3 had a role in directing white blood cells that attack solid tumors in mouse melanoma models. They found that adoptive cell transfer of cancer-specific killer T cells that overexpressed Runx3 delayed tumor growth and prolonged survival, while mouse models treated with those lacking Runx3 fared much worse than normal.
“If we enhance Runx3 activity in the cells, the tumors are significantly smaller and there is greater survival compared to the control group,” Pipkin said.
Knowing that modulating Runx3 activity in T cells influences their ability to reside in solid tumors opens new opportunities for improving cancer immunotherapy, Pipkin said.
“The upshot is we could probably use Runx3 to reprogram adoptively transferred cells to help drive them to amass in solid tumors,” he said. He added that a collaboration of specialists energized the research. “It was a fantastic collaboration, it all came together very quickly,” Pipkin said.
The Latest on: Cancer immunotherapy
- New combination treatment for recurrent ovarian cancer shows positive outcomeson November 19, 2020 at 5:10 pm
A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian ...
- Seattle biotech firm Umoja Biopharma raises $53M as it tackles unique approach to immunotherapyon November 19, 2020 at 11:59 am
Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients.
- Computational method could predict immunotherapy response in patients with advanced melanomaon November 19, 2020 at 7:21 am
A computational method that combines clinicodemographic variables with deep learning of pre-treatment histology images could predict response to immune checkpoint blockade among patients with advanced ...
- Another side to cancer immunotherapy? Scientists investigate intratumoral B cellson November 19, 2020 at 4:11 am
Immunotherapies have transformed the treatment of several types of cancer over the last decade. Yet they focus on reactivating one arm of the immune system: cytotoxic T cells, which sniff out and kill ...
- World Cancer Immunotherapy Market Analysis & Forecasts 2020-2025 with CAR T Therapy Company Case Studieson November 18, 2020 at 1:54 pm
The "Global Cancer Immunotherapy Market Analysis & Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. Within the cancer therapeutics space, which today is worth over $160 ...
- Gene Modifying Immunotherapy for Blood Cancer Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2027on November 18, 2020 at 12:33 pm
Research Nester released a report titled "Gene Modifying Immunotherapy for Blood Cancer Market: Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global gene ...
- Stage 4 lung cancer: how immunotherapy helped one local mom recoveron November 16, 2020 at 3:09 pm
"I went to my primary care because I had a sinus infection." As a smoker for 40 years Natalie went through with the chest x-ray, which showed something.
- STAT 'wunderkind' advancing fields of focused ultrasound, cancer immunotherapy (image)on November 16, 2020 at 12:45 pm
Natasha Sheybani, PhD, has been named one of the next generation of scientific superstars for her work in focused ultrasound, cancer immunology and nuclear medicine while a graduate student at the ...
- Study identifies patients with lung cancer most likely to respond to immunotherapyon November 16, 2020 at 8:02 am
Scientists are beginning to unravel one of the biggest challenges with immunotherapy: why some people with cancer respond to the treatment, while others may not respond at all.
- Society for Immunotherapy of Cancer 2020: Pushing the Boundaries of Cancer Treatmenton November 12, 2020 at 4:00 pm
New research presented at the annual meeting of the Society for Immunotherapy of Cancer annual meeting reveals new approaches to tough tumors and cancers ...
via Google News and Bing News